12th Annual Clinical Trials in Oncology West Coast 2025

The West Coast's leading Clinical Trials in Oncology Conference showcasing the most efficient methods, strategies and solutions of running oncology trials.

14 - 15

May

2025
  • San Francisco Airport Marriott Waterfront, Burlingame, CA, USA
  • Complimentary
  • Why attend?
  • Agenda
  • Speakers
  • Plan Your Visit
  • Sponsors
  • Media Centre
  • Why partner?
  • Event Gallery
  • Contact Us
close

2025 Sponsors Include:

Back

Company Information

Worldwide is changing how the world experiences CROs – in the best possible way. From early phase, bioanalytical sciences, late phase, post-approval and real-world evidence, Worldwide Clinical Trials provides full-service drug development services for central nervous system, cardiovascular, metabolic, general medicine, oncology and rare disease therapies.

Company Website

To learn more, please visit our website - https://www.worldwide.com

Next Sponsor
Back

Company Information

Scimega is a niche Canadian Oncology CRO with a singular focus on promoting and contributing to the successful conduct of cutting-edge oncology clinical trials in Canada. With a permanent, Lean-coached operations team our proven track record assisting mid-size and smaller US biotech/biopharma sponsors to undertake global oncology studies in Canada is bundled with 25 years of lessons learned!

Company Website

To learn more, please visit our website - www.scimega.com

Next Sponsor
Back

Company Information

Myonex provides tailored services and solutions to advance medicine through clinical to commercial stages with tailored drug sourcing and ancillary supply, to packaging, labeling, and distribution. With ten global locations, we offer flexible, efficient, and cost-effective support for clients across the pharmaceutical and biotech sectors.

 

Company Website

To learn more, please visit our website - www.myonex.com

Next Sponsor
Back

Company Information

You need an Imaging Strategy that’s designed and customized for your oncology clinical trial. RadMD, a Medica Group Company, is your full service imaging core lab solution. Imaging endpoints are often used to support go/no-go decision-making in early phase trials. This is also a critical time to determine the development strategy for later study phases. https://www.rad-md.net/

Company Website

To learn more, please visit our website - www.rad-md.net

Next Sponsor
Back

Company Information

OWL Oncology Research is a Functional Service Provider (FSP), comprised of a global network of highly experienced independent contractors specializing in oncology and rare disease trials. We provide Clinical Operations Support Personnel such as CRAs, Project Managers, Clinical Trial Managers, and QC Oversight Monitors to build and grow your team as an alternative to the traditional CRO approach. We are committed to providing only the best contractors through our network, hand selected for their commitment to quality and excellence.

Company Website

To learn more, please visit our website - www.owloncology.com

Next Sponsor
Back

Company Information

Jumo Health develops age-appropriate, culturally sensitive, and relatable educational resources for patients and caregivers. We have experience serving diverse populations, covering more than 160 health topics across 75+ countries and 90+ languages – and we’re always expanding!

Our multicultural offerings are designed to explain the latest in evidence-based literature using highly visual elements so that everyone can understand complex medical topics. We use familiar mediums to ensure this – from comic books and Pixar®-style animation, to virtual reality experiences and authentic documentary-style patient stories – all tailored based on age and audience.

Jumo Health collaborates globally with more than 180 advocacy groups and community organizations to ensure an authentic patient experience is accurately represented.

Company Website

To learn more, please visit our website - www.jumohealth.com

Next Sponsor
Back

Company Information

Translational Drug Development (TD2) is a world-class oncology drug development organization specializing in the development of new oncology medicines. TD2 offers fully integrated precision oncology clinical development solutions that combine the highest standards in clinical trials management, disruptive imaging, biomarker strategies, and unparalleled access to real-time patient data.

Company Website

To learn more, please visit our website - www.td2inc.com

Next Sponsor
Back

Company Information

Mercalis has a suite of Clinical Trial Support services designed to provide time and cost efficiencies.

RxStudy Card – Pharmacy provides commercially available medications and supplies through retail and specialty pharmacies. This supply strategy reduces supply process steps, requires less employee time, eliminates supply waste, and has fewer risks resulting in an 80% reduction in labor and a 50% reduction in costs.

RxStudy Card – Provider provides reimbursement for site sourced and administered medication and is essential for studies requiring biologics and oncolytics, which are more frequently being sourced directly by a provider and not through a pharmacy.

RxStudy Card – Procurement is an innovative GLOBAL clinical trial supply process that more efficiently provides commercially available medications and supplies. RxStudy Card – Procurement leverages “in country” sourcing and distribution, provides study teams and sites a simple online ordering experience for “just in time” “as needed” delivery, in quantities specific to each site and patients need with direct to site shipments and real time order and shipment status.

Company Website

To learn more, please visit our website - www.mercalis.com

Next Sponsor
Back

Company Information

Biorasi is a global contract research organization (CRO) delivering fast and flexible solutions across clinical trials to maximize speed-to-market for its sponsors. As the leader in clinical trials for dermatology, neurology, and oncology, Biorasi sets new benchmarks for speed, agility, and quality in patient enrollment, decentralized trials, and data sciences.

Next Sponsor
Back

Company Information

ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 113 locations in 53 countries as at September 30, 2022.

Company Website

To learn more, please visit our website - http://www.iconplc.com/

Next Sponsor
Back

Company Information

Adnexi is a tech-enabled principal investigator, site and key opinion leader (KOL) discovery solution for biopharma. Adnexi works with biopharma companies to improve trial site selection strategies, and achieve the inclusion of diverse patient populations. Our key solutions include:
• TRIAL VERSITY: Diverse KOL discovery to find those KOLs and principal investigators that have the most access to diverse patient populations, including African American and Hispanic populations
• BASE: Data-driven, algorithmic database of principal investigators for any disease based on massive data processing
• AIM: Adnexi influence mapping. Survey-driven influence patterns for any disease with opinion data directly from physicians

Company Website

To learn more, please visit our website - https://www.adnexi.com/

Next Sponsor
Back

Company Information

LabConnect provides global central laboratory services including routine and esoteric lab testing, kit building, sample management, biostorage and scientific support services for our biopharmaceutical clients. LabConnect’s unique combination of state-of-the-art technology, world-class laboratories, easy access to emerging markets and extensive specialized testing expertise means the drug development industry can rely on a single provider for all of their central lab needs.

Company Website

To learn more, please visit our website - http://www.labconnectllc.com/

Next Sponsor
Back

Company Information

Syneos Health (Nasdaq:SYNH*) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together, we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit SyneosHealth.com. 

Company Website

To learn more, please visit our website - www.SyneosHealth.com

Next Sponsor
Back

Company Information

Premier Research is a leading clinical development service provider that helps highly innovative biotech and specialty pharma companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, CNS, oncology, pediatric, and rare disease.

Company Website

To learn more, please visit our website - http://www.premier-research.com/

Next Sponsor

    Why attend?

    The 12th Annual Clinical Trials in Oncology West Coast 2025 is back again!

    Our West Coast Oncology event is coming back for the 12th year in Burlingame, CA, USA on 14th-15th May 2025. Expanding with a significant range of hot topics on trial diversity, reframing complex oncology trials, patient centricity and decentralized trials; our 2025 event introduces a brand new second stream focusing on patient recruitment and engagement. 

    The conference program will cover a plethora of burning topics with top experts in the industry including, Genentech, Gilead, Johnson & Johnson, BeiGene and a Venture Capitalist to share how to secure investments for your oncology trial… so come and attend to hear vital insights and opinions that you want to hear!

    WHAT TO EXPECT FOR 2025?

    What do we have for 2025?

    We have introduced and dedicated a whole new stream on patient recruitment and engagement which focuses on harnessing strategizes, communication and latest trends in Oncology clinical trials. The event will include the top industry experts to share their latest struggles and successes.

     

    250+

    Attendees

    		20+

    Exhibitors

    		20+

    Speakers
    250+

    Attendees

    		20+

    Exhibitors
    20+

    Speakers

    Testimonials

    See What It's All About

    Agenda

    • 14 May 2025
    • 15 May 2025
    Expand All

    Streams

    Stream one

    STREAM A: Clinical Operations

    Stream two

    STREAM B: Patient Recruitment and Engagement

    11 AM

    Identifying patients as equal partners and including their voice in all stages of drug development

    • Acknowledging the value that patients can bring to every stage of the drug development pathway
    • Combining patient perspectives with those of healthcare professionals to create a holistic trial model
    • Turning to patients to help reduce waste, shorten development times and ensure the right outcomes are selected and measured effectively
    • Highlighting financial incentives to amplify the patient voice

    Speakers

    Brage Garofalo
    Director of Global Clinical Study Management, Eikon Therapeutics

    11:30 AM

    Reserved for event sponsor

    12 PM

    PANEL DISCUSSION: Innovatively progressing patient-centric oncology trials in 2025

    • Strategies for advancing patient-centric trials in 2025, focusing on innovative approaches to enhance trial design and execution
    • Streamlining and improving patient involvement, communication, and the simplification of processes in trials to minimize patient burden
    • Sharing best practices to foster an engaged patient journey, ensuring patient retention throughout the trial process
    • Translating technology to tangible outcomes: What are the latest innovative technologies helping patients throughout the trial

    Speakers

    Sarah Schiltz
    Board Member, Cancer CAREpoint and Patient Advocate, National Cancer Institute
    Gay Crawford
    Founding Chair, Emeritus Member Patient and Family Advisory Council, Stanford Health Care South Bay Cancer Center
    Brage Garofalo
    Director of Global Clinical Study Management, Eikon Therapeutics
    Lloryn Hubbard
    Director Clinical Trial Diversity and Patient Voice, Daiichi Sankyo

    12:30 PM

    Technology spotlight

    12:45 PM

    Lunch and networking

    1:45 PM

    Clinical trial diversity and how it intersects with patient-centric approaches and inclusive trial designs

    Speakers

    Cynthia C. Obiozor
    Oncology Clinical Research Medical Executive Director, Amgen

    2:15 PM

    Reserved for event sponsor

    2:45 PM

    Transforming patient enrolment campaigns to make a meaningful impact on lifesaving research

    • Integrating the right biomarker to narrow relevant patient groups and optimize and personalize disease management
    • Engaging with the oncology community and advocacy groups to grow involvement of well-informed patients
    • Leveraging investigator expertise for pragmatic trial designs and patient identification
    • Building the evidence, from natural history to endpoint development, to support informed decisions by health authorities

    Speakers

    Zelanna Goldberg
    Chief Medical Officer, Replicate Bioscience

    3:15 PM

    Afternoon refreshments and networking

    3:45 PM

    Patient voice: Hear about Gay Crawford’s experience within clinical trials

    Speakers

    Gay Crawford
    Founding Chair, Emeritus Member Patient and Family Advisory Council, Stanford Health Care South Bay Cancer Center

    4:15 PM

    Reserved for event sponsor

    4:45 PM

    Strengthening clinical trial diversity to reduce inequities in trials

    • Sharing best practices for recruiting and integrating populations that are not well represented in oncology trials
    • Lessons from Advancing Inclusive Research Site Alliance collaborations
    • What strategies that pharma/biotech and vendor companies can design and support to help sites reach a more diverse patient population

    Speakers

    Meghan McKenzie
    M.A. Patient Inclusion and Health Equity, Chief Diversity Office, Genentech

    5:15 PM

    Chairperson’s closing remarks

    END OF DAY 1 AND NETWORKING DRINKS

    8 AM

    Registration and refreshments

    8:20 AM

    Chairperson’s opening remarks

    8:30 AM

    KEYNOTE: Developing resilient clinical trials: Lessons learned in CAR-T for ped-young adult and adult oncology trials

    • Working with both cooperative groups and biotechs in a harmonious way
    • How to streamline processes and improve trial design
    • Avoiding pitfalls which can have lasting global impacts
    • Setting up trials for offsite patients and ensuring remote data can be obtained

    Speakers

    Jennifer Willert
    Medical Director CART USOM, Novartis

    9 AM

    Reserved for event sponsor

    9:30 AM

    PANEL DISCUSSION: Where is the oncology clinical trial industry headed in 2025?

    • Navigating new regulations around clinical trials smoothly and successfully
    • Predictions for how the global markets will impact US studies
    • The impact of artificial intelligence: how far can we expect to move forward in the next 12 months?
    • Patient centricity in clinical trials: how can burden be reduced in order to make trials easier for patients to participate in?

    Speakers

    Anthony Fermin
    Clinical Program Director, Genentech

    10 AM

    Reserved for event sponsor

    10:30 AM

    Morning refreshments and networking

    11 AM

    New trial locations: Establishing an operational presence in new markets outside EU7

    • When the bandwidth for trials in certain places is limited, what are other regions that can host them?
    • Can we find new places to do studies?
    • Are there locations that replace Russia, Ukraine and Israel running trials are difficult?
    • A look at Asia Pacific, tapping into opportunity in new areas

    Speakers

    Faisal Rahman
    Senior Medical Director, Eikon Therapeutics

    11:30 AM

    Reserved for event sponsor

    12 PM

    How to align financial incentives between CROs and biotechs so that both sides win

    • Fine-tuning the partnership and incentivizing CROs to be more thoughtful in proposals
    • Reconsidering PM involvement and responsibilities
    • Encouraging data system investment
    • Building better budgets on the known

    Speakers

    Abhijit Ramachandran
    Director, Clinical Development Operations – Oncology, Corcept Therapeutics

    12:30 PM

    Technology spotlight

    12:45 PM

    Lunch and networking

    1:45 PM

    Rethinking the paradigm and turning to RBQM for a risk-based, more targeted, and more efficient approach to clinical research in oncology

    • Knowing how to pick the right level of risk adjustment and critical to quality factors for your study
    • RBQM and vendors: how can we better work together to avoid common pitfalls and improve TMF quality
    • Why has there been a burdening resistance to adopting RBQM?
    • Understanding the latest regulation, ICH E6(R3), and how it’s designed to support better trial design, quality, patient safety and to better ensure compliance
    • How can RBQM help sponsors manage high clinical trial complexity?

    Speakers

    Catherine Caserza
    Director, Clinical Operations, Daichii Sankyo

    2:15 PM

    Reserved for event sponsor

    2:45 PM

    FDA regulations in decentralized clinical trials

    • An overview of the FDA's latest guidelines and requirements for DCTs, highlighting key aspects such as the integration of digital health technologies, remote monitoring, and the adherence to Good Clinical Practice (GCP) principles, as well as ensuring innovative trials maintain the highest standards of safety, efficacy, and data integrity.
    • Discussion of the FDA's collaborative efforts with other regulatory bodies, promoting harmonized standards and facilitating global acceptance of DCT methodologies.
    • Adhering to the FDA's comprehensive regulatory requirements so sponsors can navigate the complexities of DCTs and contribute to the evolution of clinical trials and the accelerated development of innovative medical treatments

    Speakers

    Wenjing Wang
    Associate Director - Associate Principal Scientist, Merck

    3:15 PM

    Afternoon refreshments and networking

    3:45 PM

    FIRESIDE CHAT: When sites aren’t delivering, what’s the outlook for timely drug development in oncology?

    • Building a partnership reciprocity between sites and sponsors to reduce discord and ensure sites are confident enough to succeed
    • Is it fair to place the shortcomings of trial success on site performance?
    • Equipping sites with a clear and well-defined protocols to be able to best respond to sponsor needs
    • Strategies and case stories for improving site engagement and management in 2025

    Speakers

    Kathy Benton
    Associate Director, Study Site Engagement Lead, Takeda

    4:15 PM

    Reserved for event sponsor

    4:45 PM

    Get to know your CRO

    • Are global CROs the only viable solution for multinational drug development clinical trials?
    • Avoiding the misalignment of incentives between service providers and biotechs to prevent sponsor dissatisfaction
    • Thinking objectively when selecting CRO partnerships by using a data-based approach rather than relying on previous relationships and trials
    • From chaos to clarity: How to best implement innovative e-clinical software systems to ensure they work within the CRO universe

    Speakers

    Brian Frenzel
    President, CEO, and Director, Tosk

    5:15 PM

    Chairperson’s closing remarks

    END OF DAY 1 AND NETWORKING DRINKS

    8 AM

    Registration and refreshments

    8:50 AM

    Chairperson’s opening remarks

    9 AM

    Interactive Speaker-Hosted Roundtable Discussions

    Interactive roundtable sessions offer a unique opportunity to come together with your peers to share best practice and develop solutions to critical challenges facing the industry as a whole. Each discussion will be led by a table moderator and will focus on a different challenge within oncology clinical trials. Roundtables are an exciting, interactive way to build your personal network and learn from the experience and expertise of others.

    After 30 minutes, delegates will have the opportunity to swap and choose a different table, and each roundtable will run twice.

    Roundtable 1 Balancing patient, development and investor priorities in your trial design
    Roundtable 2 Measuring success by assessing the effectiveness of your patient enrolment strategy
    Roundtable 3 Economics of trial start up: True cost of no diversity, lack of technology adoption and more
    Roundtable 4 Ensuring regulatory compliance for expedited drug approvals in oncology in the USA

    10 AM

    Morning refreshments and networking

    10:30 AM

    KEYNOTE: Clinical Trial Decarbonization: beginning our journey to NetZero

    • Measuring clinical trial carbon emission footprints
    • Identifying emissions hotspots and decarbonization initiatives
    • Aligning with key partners (e.g. CRO, Central Lab)
    • Incentivizing the organization

    Speakers

    Edward Owen
    Therapeutic Area Director, Oncology, Early Clinical Development, Genentech

    11 AM

    Reserved for event sponsor

    11:30 AM

    PANEL DISCUSSION: How innovation will shape the future of clinical research in oncology

    • Assessing the value of innovation in oncology trials: sharing best practice on engaging sites with new technology
    • Leveraging the latest technologies to enhance patient experience
    • Training sites and staff on new systems to maximize the benefits of the latest technology and streamline processes
    • Assessing the efficiency and success of pragmatic trials for more patient-centered approaches: do they work for oncology?

    Speakers

    Abhijit Ramachandran
    Director, Clinical Development Operations – Oncology, Corcept Therapeutics
    Edward Owen
    Therapeutic Area Director, Oncology, Early Clinical Development, Genentech

    12 PM

    Reserved for event sponsor

    12:30 PM

    Lunch and networking

    1:30 PM

    CARGO’s CAR-T related trials

    Speakers

    Cedric Dos Santos
    Vice President, Translational Medicine, CARGO Therapeutics

    2 PM

    Reserved for event sponsor

    2:30 PM

    PANEL DISCUSSION: The pursuit of success: Driving your drug from the bench to bedside

    • Defining what do we do well and what could be improved – EU vs US focus
    • Planning and preparation within oncology drug trials – focus on phase 2/3
    • Choosing the right trial designs for rare disease studies
    • How to achieve a successful launch by building appropriate phase 3

    Speakers

    Wenjing Wang
    Associate Director - Associate Principal Scientist, Merck
    Dr. Kumar Gadamasetti
    CEO, Certum Bio

    3 PM

    Afternoon break, networking and prize draw

    3:30 PM

    Effective collaboration in the trial ecosystem: How should pharma work with patient organizations and what are the best ways to engage with them?

    • Highlighting and overcoming the pitfalls of working with patient groups and how to facilitate the outreach to ensure everyone is onboard
    • Tackling lack of patient awareness: Improved methods of connecting community‐based researchers with those in academic centers conducting trials
    • Elevating trial credibility by better working with networks globally to find patients and identify the best centers

    Speakers

    Vicki Plaks
    Senior Scientific Director, Head of Cell Therapy, Oncology Translational Research, Johnson & Johnson

    4 PM

    The ongoing road to clinical trials from a startup perspective: bench to bedside with a novel pan-cancer target

    Speakers

    Gary Johanning
    CSO, SunnyBay Biotech
    Feng Wang-Johanning
    CEO, SunnyBay Biotech

    4:30 PM

    Session reserved for GlobalData

    5 PM

    Chairperson’s closing remarks

    END OF CONFERENCE

    Speakers

    Select a speaker to learn more

    Back
    Brian Frenzel
    President, CEO, and Director, Tosk

    Silicon Valley entrepreneur, board member, and private investor. Extensive experience in founding and financing new companies and improving performance of existing companies.

    Have previously served as CEO, Chairman, COO and/or CFO of four successful start-up companies that achieved an exit for investors, either through M&A or IPO. Functional areas of expertise include: general management, product development, fundraising, licensing, finance, marketing strategy, and governance.

    Specialties: Managing the start-up and high growth process, research and product development strategy, team-building, and M&A / IPO preparation and implementation.

    Session Details:

    Get to know your CRO

    2025-05-14, 4:45 PM

    View In Agenda
    Next speaker
    Back
    Edward Owen
    Therapeutic Area Director, Oncology, Early Clinical Development, Genentech

    Session Details:

    PANEL DISCUSSION: How innovation will shape the future of clinical research in oncology

    2025-05-15, 11:30 AM

    Session Details:

    KEYNOTE: Clinical Trial Decarbonization: beginning our journey to NetZero

    2025-05-15, 10:30 AM

    View In Agenda
    Next speaker
    Back
    Jennifer Willert
    Medical Director CART USOM, Novartis

    Session Details:

    KEYNOTE: Developing resilient clinical trials: Lessons learned in CAR-T for ped-young adult and adult oncology trials

    2025-05-14, 8:30 AM

    View In Agenda
    Next speaker
    Back
    Dr. Kumar Gadamasetti
    CEO, Certum Bio

    Session Details:

    PANEL DISCUSSION: The pursuit of success: Driving your drug from the bench to bedside

    2025-05-15, 2:30 PM

    View In Agenda
    Next speaker
    Back
    Lloryn Hubbard
    Director Clinical Trial Diversity and Patient Voice, Daiichi Sankyo

    Session Details:

    PANEL DISCUSSION: Innovatively progressing patient-centric oncology trials in 2025

    2025-05-14, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Zelanna Goldberg
    Chief Medical Officer, Replicate Bioscience

    Senior Executive with extensive knowledge and experience in oncology drug development. Over 20 years in oncology care and drug development across a broad platform of solid tumor and hematologic indications and drug types. Strategic thinker coupled with tactical experience across the oncology drug development landscape. Experience in small biotech and large pharma industry domains, with knowledge of asset valuation, global drug development, risk management and organizational efficiency.

    Session Details:

    Transforming patient enrolment campaigns to make a meaningful impact on lifesaving research

    2025-05-14, 2:45 PM

    View In Agenda
    Next speaker
    Back
    Cedric Dos Santos
    Vice President, Translational Medicine, CARGO Therapeutics

    Highly motivated Ph.D. research scientist with 9+ years of pre-clinical and translation research in the field of Hematology/Oncology, especially Acute Myeloid Leukemia (AML).

    Expert in normal/ malignant stem cells, signal transduction, biomarkers and drug discovery/drug development using small molecules or cancer immunotherapy both in vitro and in vivo. Strong ability to plan, develop, and execute pre-clinical studies for oncology drugs with excellent communication skills, presentation abilities and work ethic.
    Success driven team player able to work under pressure in order meet deadlines. Established collaborations with both academic and pharmaceutical companies.

    With an ambitious personality, my goal is to develop selective therapeutic strategies for targeting AML/cancer stem cells in order to start clinical trials and improve patients’ outcome. As a proof, one of my preclinical study led to a phase I/II clinical trial combining dasatinib with conventional chemotherapy aimed at improving outcomes in poor-risk AML patients that otherwise have low remission rates and high relapse rates (NCT01876953).

    Specialties: Hematological malignancies, especially AML, CML and MDS.
    Normal hematopoietic and leukemic stem cells isolation/characterization, signaling pathways, AML/MDS patient-derived xenograft model and syngeneic/GEMM AML mouse model.
    Pre-clinical, clinical and translational research.

    Session Details:

    CARGO’s CAR-T related trials

    2025-05-15, 1:30 PM

    View In Agenda
    Next speaker
    Back
    Faisal Rahman
    Senior Medical Director, Eikon Therapeutics

    Session Details:

    New trial locations: Establishing an operational presence in new markets outside EU7

    2025-05-14, 11:00 AM

    View In Agenda
    Next speaker
    Back
    Luis A. Aguilar
    Vice President, Business and Clinical Operations, Candel Therapeutics
    Next speaker
    Back
    Catherine Caserza
    Director, Clinical Operations, Daichii Sankyo

    Session Details:

    Rethinking the paradigm and turning to RBQM for a risk-based, more targeted, and more efficient approach to clinical research in oncology

    2025-05-14, 1:45 PM

    View In Agenda
    Next speaker
    Back
    Wenjing Wang
    Associate Director - Associate Principal Scientist, Merck

    Session Details:

    PANEL DISCUSSION: The pursuit of success: Driving your drug from the bench to bedside

    2025-05-15, 2:30 PM

    Session Details:

    FDA regulations in decentralized clinical trials

    2025-05-14, 2:45 PM

    View In Agenda
    Next speaker
    Back
    Sarah Schiltz
    Board Member, Cancer CAREpoint and Patient Advocate, National Cancer Institute

    With over 30 years of experience in healthcare technology, I currently serve as a patient advocate and board member for organizations committed to driving positive change in healthcare and supporting those impacted by cancer. Previously, I held the position of marketing leader at Vocera Communications, a public company based in Silicon Valley. Following Vocera's acquisition by Stryker in February 2022, I provided advisory support during the transition throughout 2023.

    I dedicate my time and energy to enhancing the lives of cancer patients and the front-line caregivers who support them.

    'An experienced and passionate patient and caregiver advocate, helping improve the lives of those that have followed in her path on a cancer journey.  Motivational leader with record of success creating, executing, and managing programs that lead to immediate and long-term results. Experience building marketing divisions from the ground up, leading turnarounds for under-performing areas, and building consensus to advance adoption of services and technologies.'

    Session Details:

    PANEL DISCUSSION: Innovatively progressing patient-centric oncology trials in 2025

    2025-05-14, 12:00 PM

    View In Agenda
    Next speaker
    Back
    Brage Garofalo
    Director of Global Clinical Study Management, Eikon Therapeutics

    Session Details:

    PANEL DISCUSSION: Innovatively progressing patient-centric oncology trials in 2025

    2025-05-14, 12:00 PM

    Session Details:

    Identifying patients as equal partners and including their voice in all stages of drug development

    2025-05-14, 11:00 AM

    View In Agenda
    Next speaker
    Back
    Abhijit Ramachandran
    Director, Clinical Development Operations – Oncology, Corcept Therapeutics

    Abhijit Ramachandran, Director of Clinical Operations at Corcept Therapeutics Inc. is an established versatile leader with deep experience in clinical trial operations management. Expertise in conducting and coordinating multi-center international clinical trials and managing cross-functional project teams. Highly skilled in liaising with Contract Research Organizations (CROs) and other suppliers to achieve program and company goals. Adept at managing the progress of clinical studies and ensuring adherence to study protocols, regulatory/internal SOPs, intended timelines, and budget. Solid experience with early and late-phase clinical studies, including orphan disease indications.

    Session Details:

    How to align financial incentives between CROs and biotechs so that both sides win

    2025-05-14, 12:00 PM

    Session Details:

    PANEL DISCUSSION: How innovation will shape the future of clinical research in oncology

    2025-05-15, 11:30 AM

    View In Agenda
    Next speaker
    Back
    Anthony Fermin
    Clinical Program Director, Genentech

    Clinical research professional with a pharmacy and nursing background experienced in managing clinical development studies in multiple therapeutic areas specializing in oncology in a fast-paced, cross-functional environment.

    Session Details:

    PANEL DISCUSSION: Where is the oncology clinical trial industry headed in 2025?

    2025-05-14, 9:30 AM

    View In Agenda
    Next speaker
    Back
    Meghan McKenzie
    Director of Health Equity and Clinical Research, Chief Diversity Office, Genentech

    Meghan McKenzie is a Director of Health Equity and Clinical Research in Genentech’s Chief Diversity Office. She develops strategies to drive greater inclusion of underrepresented patient populations in clinical research and to advance health equity by working directly with sites in our Advancing Inclusive Research (AIR) Site Alliance and by gaining patient insights to change behavior and protocols.

    Gaining patient, clinician and community insights early in program development is integral to developing what is important to patients and improving access to medicines and treatments for all patients, regardless of race, ethnicity, sexual orientation, gender identity, age, disability and socioeconomic status.

    She has over 25 years of clinical development research experience working at the site, CRO and biotech level, and spanning multiple diseases, including oncology, ophthalmology, immunology, neurology, infectious and rare diseases.

    Meghan received her Master’s Degree in Human Biology at San Francisco State University and her Bachelor’s Degree in Economics at University of North Carolina, Chapel Hill and has earned the Cornell University ‘Advanced D&I Certificate’ and the Columbia Business School ‘Certificate in Business Excellence

    Next speaker
    Back
    Kathy Benton
    Associate Director, Study Site Engagement, Takeda
    Next speaker
    Back
    Cynthia C. Obiozor
    Oncology Clinical Research Medical Executive Director, Amgen

    Physician life sciences and drug development strategist providing clinical insight and direct oversight of multi country clinical trials, expanded access protocols, diagnostics, and therapeutic collaborations in the oncology sector.

    Notable Therapeutics:
    SD-101,  Toll-like receptor 9 agonist, inducing inflammatory antitumor immune responses and has demonstrated clinical synergy with anti-PD-1 antibodies in PD-1 Ab-naïve and PD-1 Ab-refractory melanoma and in patients with anti-PD-1/PD-L1 naïve, recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

    LUMAKRAS (soratasib), first in class KRAS G12C inhibitor indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).

    Notable Diagnostics:
    Therascreen Qiagen RGQ PCR (an FDA-approved companion diagnostic (CDx) test to identify NSCLC patients harboring specific KRAS mutations in tumor DNA isolated from formalin-fixed paraffin-embedded (FFPE) NSCLC tumor tissue and that may be eligible for treatment with LUMAKRAS (soratasib).

    Session Details:

    Clinical trial diversity and how it intersects with patient-centric approaches and inclusive trial designs

    2025-05-14, 1:45 PM

    View In Agenda
    Next speaker
    Back
    Gay Crawford
    Founding Chair, Emeritus Member Patient and Family Advisory Council, Stanford Health Care South Bay Cancer Center

    A two-time cancer survivor, Crawford, a media professional amd a member of the Rotary Club of San Jose,  is most noted for “changing the landscape” of cancer care in Silicon Valley and California.  She served on the American Cancer Society’s National Extramural Grants programs a Stakeholder, helping to award some $100 million research dollars.  She is a founder of the second non-profit hospice in California; she found  an annual program serving 400 kids with cancer every year; she is the founder and firs president of  the Cancer Registry for the State of California, and an Emeritus member of Stanford Cancer Center South Bay’s Patient and Family Advisory Council.   Inn 2009,  she co-founded Cancer CAREpoint, which provides free non-medical services for cancer patients and families in the Bay Area and currently serves on their Advisory Sustaining Board.

    Crawford has many awards to her credit, including the National Ellen Stovall Award for Innovation in Cancer Care, (a national award for cancer patient advocacy). She was selected by KRON TV for their 2024  Remarkable Woman program; The Jefferson Award from KPIX TV CBS, in 2014 she was selected for the Citizen’s Award from Santa Clara County Medical Association; the Silicon Valley Business Journal named her a Woman of Influence in 2015 and she has received numerous honors from the American Cancer Society, where she is an honorary life member.

    Session Details:

    PANEL DISCUSSION: Innovatively progressing patient-centric oncology trials in 2025

    2025-05-14, 12:00 PM

    Session Details:

    Patient voice: Hear about Gay Crawford’s experience within clinical trials

    2025-05-14, 3:45 PM

    View In Agenda
    Next speaker
    Back
    Vicki Plaks
    Senior Scientific Director, Head of Cell Therapy, Oncology Translational Research, Johnson & Johnson

    Session Details:

    Effective collaboration in the trial ecosystem: How should pharma work with patient organizations and what are the best ways to engage with them?

    2025-05-15, 3:30 PM

    View In Agenda
    Next speaker
    Back
    Gary Johanning
    CSO, SunnyBay Biotech

    Basic research on the role of viruses in the development of cancer. Studying how ancient endogenous retroviruses, which are present in all humans, become overexpressed in breast, ovarian, pancreatic and other cancers. Evaluating the efficacy of therapeutic antibodies and other therapies aimed at blocking human endogenous retrovirus expression in cancer cells.

    Session Details:

    The ongoing road to clinical trials from a startup perspective: bench to bedside with a novel pan-cancer target

    2025-05-15, 4:00 PM

    View In Agenda
    Next speaker
    Back
    Feng Wang-Johanning
    CEO, SunnyBay Biotech

    Session Details:

    The ongoing road to clinical trials from a startup perspective: bench to bedside with a novel pan-cancer target

    2025-05-15, 4:00 PM

    View In Agenda
    Next speaker

    Plan Your Visit

    Venue

    San Francisco Airport Marriott Waterfront

    1800 Old Bayshore Highway Burlingame, California, USA, 94010

    Book Your Stay

    Accommodation

    Arena International Events Group “(Arena”) is aware of numerous third party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings and events attendee lists. For the avoidance of doubt, Arena will only share attendee lists with carefully selected third party partners for event registration purposes. Whilst Arena International Events Group pursues third party agencies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group..

    Sponsors

    Select a sponsor to learn more

    FEATURED SPONSORS

    SESSION SPONSORS

    coffee break sponsor

    ROUNDTABLE SPONSOR

    EXHIBITORS

    co-sponsor

    Why partner?

    Contact us to become a partner

    Partnership Opportunities

    We work with you to design a bespoke package to meet your business needs, where you could:

    • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
    • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
      Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
    • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

    Event reach

    • 150+ attendees each year
    • 80% attendees C-suite level

     

    Take a look at our current sponsors

    Media Centre

    Enquiry

    Contact Us

    SPONSORSHIP ENQUIRIES

    Conor Taylor

    Sponsorship Sales Manager

    +44 (0) 20 7936 6870

    SPEAKING OPPORTUNITIES

    Niki Khoshkbary

    Senior Conference Producer

    +44 204540 7545

    MARKETING ENQUIRIES

    Moona Popal

    Marketing Manager

    DELEGATE ENQUIRIES

    Sunny Saikia

    VIP Delegate Manager

    SPONSORSHIP ENQUIRIES

    To enquire about sponsorship opportunities for the conference, please contact:

    Conor Taylor

    Sponsorship Sales Manager


    +44 (0)207 936 6870

    SPEAKER ENQUIRIES

    To enquire about speaking opportunities for the conference, please contact:

    Niki Khoshkbary

    Senior Conference Producer


    +44 204540 7545